Heart failure algorithms for remote monitoring in people with cardiac implantable electronic devices (DG61)Product type:GuidanceProgramme:Diagnostics guidancePublished: 24 October 2024
Empagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction (TA929)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 1 November 2023
Dapagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction (TA902)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 21 June 2023
TYRX Absorbable Antibacterial Envelope for preventing infection from cardiac implantable electronic devices (terminated appraisal) (TA790)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 25 May 2022
Empagliflozin for treating chronic heart failure with reduced ejection fraction (TA773)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 9 March 2022
Sodium zirconium cyclosilicate for treating hyperkalaemia (TA599)Product type:GuidanceProgramme:Technology appraisal guidanceLast updated: 24 January 2022Published: 4 September 2019
Percutaneous implantation of pulmonary artery pressure sensors for monitoring treatment of chronic heart failure (IPG711)Product type:GuidanceProgramme:Interventional procedures guidancePublished: 24 November 2021
Acute heart failure: diagnosis and management (CG187)Product type:GuidanceProgramme:Clinical guidelineLast updated: 17 November 2021Published: 8 October 2014
Vericiguat for treating chronic heart failure with reduced ejection fraction (terminated appraisal) (TA731)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 29 September 2021
ENDURALIFE powered CRT-D devices for treating heart failure (MTG33)Product type:GuidanceProgramme:Medical technologies guidanceLast updated: 21 July 2021Published: 17 March 2017
Permanent His-bundle pacemaker implantation for treating heart failure (IPG694)Product type:GuidanceProgramme:Interventional procedures guidancePublished: 5 May 2021
Dapagliflozin for treating chronic heart failure with reduced ejection fraction (TA679)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 24 February 2021
Electrical stimulation to improve muscle strength in chronic respiratory conditions, chronic heart failure and chronic kidney disease (IPG677)Product type:GuidanceProgramme:Interventional procedures guidancePublished: 5 August 2020
Patiromer for treating hyperkalaemia (TA623)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 13 February 2020
Cardiac contractility modulation device implantation for heart failure (IPG655)Product type:GuidanceProgramme:Interventional procedures guidancePublished: 26 June 2019
Percutaneous mitral valve leaflet repair for mitral regurgitation (IPG649)Product type:GuidanceProgramme:Interventional procedures guidancePublished: 29 May 2019
Chronic heart failure in adults: diagnosis and management (NG106)Product type:GuidanceProgramme:NICE guidelinePublished: 12 September 2018
Artificial heart implantation as a bridge to transplantation for end-stage refractory biventricular heart failure (IPG602)Product type:GuidanceProgramme:Interventional procedures guidancePublished: 20 December 2017
Sacubitril valsartan for treating symptomatic chronic heart failure with reduced ejection fraction (TA388)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 27 April 2016
Normothermic extracorporeal preservation of hearts for transplantation following donation after brainstem death (IPG549)Product type:GuidanceProgramme:Interventional procedures guidancePublished: 24 February 2016
Implantation of a left ventricular assist device for destination therapy in people ineligible for heart transplantation (IPG516)Product type:GuidanceProgramme:Interventional procedures guidancePublished: 27 March 2015
Implantable cardioverter defibrillators and cardiac resynchronisation therapy for arrhythmias and heart failure (TA314)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 25 June 2014
Extracorporeal membrane oxygenation (ECMO) for acute heart failure in adults (IPG482)Product type:GuidanceProgramme:Interventional procedures guidancePublished: 27 March 2014
Ivabradine for treating chronic heart failure (TA267)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 28 November 2012
Percutaneous mitral valve annuloplasty (IPG352)Product type:GuidanceProgramme:Interventional procedures guidancePublished: 28 July 2010
Short-term circulatory support with left ventricular assist devices as a bridge to cardiac transplantation or recovery (IPG177)Product type:GuidanceProgramme:Interventional procedures guidancePublished: 28 June 2006
Partial left ventriculectomy (the Batista procedure) (IPG41)Product type:GuidanceProgramme:Interventional procedures guidancePublished: 25 February 2004
The OPTIMIZER smart system for managing heart failure (MIB186)Product type:AdviceProgramme:Medtech innovation briefingPublished: 27 June 2019
Remote ECG interpretation consultancy services for cardiovascular disease (MIB152)Product type:AdviceProgramme:Medtech innovation briefingPublished: 27 July 2018
CentriMag for heart failure (MIB92)Product type:AdviceProgramme:Medtech innovation briefingPublished: 18 January 2017
The AutoPulse non-invasive cardiac support pump for cardiopulmonary resuscitation (MIB18)Product type:AdviceProgramme:Medtech innovation briefingPublished: 12 February 2015
Chronic heart failure in adults (QS9)Product type:Quality standardLast updated: 10 January 2023Published: 29 June 2011
Venoarterial extracorporeal membrane oxygenation (VA ECMO) for acute heart failure in adultsStatus:In developmentProgramme:Interventional procedures guidanceExpected publication date: 6 August 2025
Sodium zirconium cyclosilicate for treating hyperkalaemia (partial review of TA599) [ID6439]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 13 August 2025
Implantable Vagus Nerve Stimulator in Heart FailureStatus:Topic selectionProgramme:Interventional procedures guidanceExpected publication date: TBC
Rivaroxaban for treating chronic heart failure [ID1462]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Omecamtiv mecarbil for treating chronic heart failure with reduced ejection fraction [ID3912 ]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Sacubitril valsartan for treating chronic heart failure with reduced ejection fraction in people under 18 years TS ID 10350Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC
Semaglutide for treating obesity-related heart failure with preserved ejection fraction TS ID 11788Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC
Empagliflozin for preventing cardiovascular events after acute myocardial infarction [ID6240]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Chronic heart failure in adults: diagnosis and management - Pharmacological treatment of chronic heart failureStatus:In developmentProgramme:NICE guidelineExpected publication date: TBC
An aortic cuff counterpulsation system for the treatment of heart failureStatus:Topic selectionProgramme:Interventional procedures guidanceExpected publication date: TBC
Ambulatory pulmonary artery pressure monitoring devicesStatus:Awaiting developmentProgramme:Diagnostics guidanceExpected publication date: TBC
Evolocumab for preventing major cardiovascular events in people aged 50 to 79 at high risk who have not had a myocardial infarction or stroke TS ID 11920Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Digital platforms to support cardiac rehabilitationStatus:Awaiting developmentProgramme:Health technology evaluationExpected publication date: TBC
Virtual Wards for Heart FailureStatus:Awaiting developmentProgramme:Medical technologies guidanceExpected publication date: TBC
Insertion of a Catheter based intravascular microaxial blood pump for acute heart failureStatus:Awaiting developmentProgramme:Interventional procedures guidanceExpected publication date: TBC
Finerenone for treating heart failure with preserved or mildly reduced ejection fraction TS ID 12051Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC